Cannabis Testing Services Market, By Test Type (Potency Testing, Terpene Profiling, Cannabinoid Profiling, Pesticide Screening, Residual Solvent Testing, Microbiological Screening, and Others), By End Use (Testing Laboratories, Research Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI2976

Pages :237

Formats :

Excel and PDF

Industry : Pharmaceutical

Cannabis Testing Services Market Size and Trends

Global cannabis testing services market is estimated to be valued at USD 2.71 Bn in 2025 and is expected to reach USD 6.79 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 14.0% from 2025 to 2032.

Cannabis Testing Services Market Key Factors

To learn more about this report, Request sample copy

The cannabis testing services market is expected to witness significant growth during the forecast period. With the growing cultivation and use of both medical and recreational cannabis, the need for the testing of various product attributes is increasing. Factors such as varying laws pertaining to the use and sale of cannabis products in different regions, rising focus on ensuring product safety and quality, and the introduction of new testing technologies will support the demand for cannabis testing services. Several countries and states are establishing standardized testing and certification programs which is also expected to boost the market growth. However, challenges such as lack of regulatory standards and inconsistencies in state and national regulations may hamper the market growth during the forecast period.

Rising Cannabis-based Drugs Approvals

Rising cannabis-based drugs approvals are projected to drive the market growth during the forecast period. For instance, in August 2020, GW Pharmaceuticals plc., the world leader company in science and development, along with its U.S.-based subsidiary, Greenwich Biosciences, Inc., declared that the U.S. Food and Drug Administration (FDA) had approved EPIDIOLEX (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.